ORLANDO — Autologous hematopoietic stem cell transplantation appeared safe and effective for older patients with multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
The study — the largest to examine autologous HSCT for older adults with multiple myeloma — showed patients aged 70 years and older achieved outcomes after transplant comparable to those of patients aged 60 to 69 years.
This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2020 Healio All Rights Reserved.